ONCY

Oncolytics Biotech

0.8701 USD
-0.0119
1.35%
Updated Dec 5, 3:17 PM EST
1 day
-1.35%
5 days
-5.42%
1 month
-26.26%
3 months
-11.93%
6 months
-18.68%
Year to date
-34.08%
1 year
-37.85%
5 years
-23.68%
10 years
45.14%
 

About: Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.

Employees: 27

0
Funds holding %
of 6,790 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0% more funds holding

Funds holding: 41 [Q2] → 41 (+0) [Q3]

0% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 7

0.36% less ownership

Funds ownership: 1.91% [Q2] → 1.55% (-0.36%) [Q3]

22% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 9

24% less capital invested

Capital invested by funds: $1.43M [Q2] → $1.1M (-$337K) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$5
475%
upside
Avg. target
$5
475%
upside
High target
$5
475%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Patrick Trucchio
52% 1-year accuracy
56 / 107 met price target
475%upside
$5
Buy
Reiterated
14 Nov 2024
HC Wainwright & Co.
Patrick Trucchio
52% 1-year accuracy
56 / 107 met price target
475%upside
$5
Buy
Reiterated
19 Sept 2024

Financial journalist opinion

Based on 4 articles about ONCY published over the past 30 days

Neutral
PRNewsWire
2 days ago
Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort
Early safety and tolerability results from six randomized patients support continued enrollment of pelareorep combined with modified FOLFIRINOX, with or without atezolizumab The study will begin with 30 patients, with an option to expand to an additional 34 participants SAN DIEGO and CALGARY, AB , Dec. 3, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that the Data Safety Monitoring Board (DSMB) has recommended continued enrollment in Cohort 5 of the GOBLET study following their review of initial safety data. Enrollment in this cohort will resume pending final approval from the Paul Ehrlich Institute (PEI), Germany's medical regulatory body.
Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort
Neutral
Seeking Alpha
3 weeks ago
Oncolytics Biotech Inc. (ONCY) Q3 2024 Earnings Call Transcript
Oncolytics Biotech Inc. (ONCY) Q3 2024 Earnings Call Transcript
Oncolytics Biotech Inc. (ONCY) Q3 2024 Earnings Call Transcript
Neutral
PRNewsWire
3 weeks ago
Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights
BRACELET-1 data showing impressive overall survival benefit in HR+/HER2- metastatic breast cancer affirms pelareorep + paclitaxel combination should be evaluated in a registrational study Upcoming GOBLET milestones include updated efficacy data from anal cancer cohort and safety run-in data from the modified FOLFIRINOX pancreatic cancer cohort Cash position of $19.6 million as of September 30, 2024 Management hosting conference call and webcast today at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , Nov. 12, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced third quarter financial results and operational highlights.
Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights
Neutral
PRNewsWire
3 weeks ago
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights
Conference call and webcast to take place on Tuesday, November 12, 2024, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , Nov. 11, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Tuesday, November 12, 2024, at 8:30 a.m.
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights
Positive
Zacks Investment Research
1 month ago
ONCY Stock Up on Regulatory Update From Breast Cancer Program
Oncolytics stock soars as the company seeks an accelerated approval pathway for its lead candidate, pelareorep, to treat a breast cancer indication.
ONCY Stock Up on Regulatory Update From Breast Cancer Program
Neutral
PRNewsWire
2 months ago
Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path
Recent clinical efficacy results from the BRACELET-1 trial in HR+/HER2- breast cancer pave the way for a clinical study designed to support an accelerated approval Key milestones in gastrointestinal cancer clinical trials expected in 2025, with potential for new registration-enabling studies SAN DIEGO and CALGARY, AB , Oct. 4, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, is issuing a corporate update to provide investors with a deeper understanding of recent data and what is expected for 2025.  "We're excited by the recent BRACELET-1 results, which exceeded our expectations and substantiate the strong efficacy signal previously observed in breast cancer patients treated with pelareorep," said Wayne Pisano, Interim CEO and Chair of Oncolytics' Board of Directors.
Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path
Neutral
PRNewsWire
2 months ago
Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study
Overall survival (OS) results from BRACELET-1 corroborate results of previous randomized IND-213 breast cancer study Together, these two studies support the compelling potential of pelareorep-based combination therapy to benefit patients with advanced or metastatic HR+/HER2- breast cancer Oncolytics Biotech is moving forward to secure funding for a registration-enabling study of pelareorep-based therapy in advanced or metastatic breast cancer Over half of BRACELET-1 patients in the pelareorep + chemotherapy arm alive at study end Median OS in the pelareorep + chemotherapy arm not reached; median OS at least 32 months (estimated) vs 18 months for the control chemotherapy-only arm SAN DIEGO and CALGARY, AB , Sept. 19, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced positive clinical results from BRACELET-1, its randomized Phase 2 study evaluating pelareorep in patients with HR+/HER2- advanced or metastatic breast cancer.
Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study
Neutral
PRNewsWire
2 months ago
Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September
SAN DIEGO and CALGARY, AB , Sept. 6, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Chief Financial Officer Kirk Look will participate in a fireside chat at the H.C.
Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September
Neutral
PRNewsWire
4 months ago
Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference
SAN DIEGO and CALGARY, AB , Aug. 2, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Chief Medical Officer Dr. Thomas Heineman will participate in a fireside chat at Canaccord Genuity's 44th Annual Growth Conference, which is taking place August 13-15, 2024 at the InterContinental Boston Hotel in Boston, MA. Additional details on the fireside chat can be found below.
Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference
Neutral
Seeking Alpha
4 months ago
Oncolytics Biotech Inc. (ONCY) Q2 2024 Earnings Call Transcript
Oncolytics Biotech Inc. (NASDAQ:ONCY ) Q2 2024 Results Conference Call August 1, 2024 4:30 PM ET Company Participants Jon Patton - Director of Investor Relations and Communication Wayne Pisano - Chair of Oncolytics' Board of Directors, and Interim CEO Tom Heineman - Chief Medical Officer Christophe Degois - Vice President Business Development Kirk Look - Chief Financial Officer Conference Call Participants John Newman - Canaccord Soumit Roy - Jones Research Michael Okunewitch - Maxim Group Rahul Sarugaser - Raymond James Operator Good afternoon, and welcome to Oncolytics Biotech Second Quarter 2024 Conference Call. All participants are now in a listen-only mode.
Oncolytics Biotech Inc. (ONCY) Q2 2024 Earnings Call Transcript
Charts implemented using Lightweight Charts™